A retrospective study of 22 patients who had surgical treatment for recurrent ameloblastoma of the jaws at our clinic, within a period of 16 years, was carried out. (1) The recurrent lesion in 18 patients was due to an inadequate previous operation; (2) massive soft-tissue recurrences even after wide mandibular resection occurred in 4 patients; and (3) a malignant transformation was noted in 1 patient.

Download full-text PDF

Source
http://dx.doi.org/10.1097/00006534-198005000-00006DOI Listing

Publication Analysis

Top Keywords

recurrent ameloblastoma
8
ameloblastoma jaws--a
4
jaws--a review
4
review cases
4
cases retrospective
4
retrospective study
4
study patients
4
patients surgical
4
surgical treatment
4
treatment recurrent
4

Similar Publications

Ameloblastoma is a benign odontogenic epithelial tumor characterized by its aggressive behavior and a high likelihood of local recurrence if not fully excised. Ameloblastomas are a common type of slow-growing, true jaw tumor which may present as solid, multicystic or unicystic forms and originate from odontogenic epithelium and exhibit a variety of histological patterns. Keratoameloblastoma is considered to be a rare variant of ameloblastoma associated with more intense keratinization.

View Article and Find Full Text PDF

Background: Ameloblastoma is a benign odontogenic neoplasm with a high recurrence rate. Identifying cellular and molecular changes in this neoplasm may help predict the recurrence risk. Bcl-2 and galectin-3 are anti-apoptotic proteins associated with the prognosis of many neoplasms.

View Article and Find Full Text PDF

From pathogenesis to precision medicine: Transformative advances in research and treatment of ameloblastoma.

Cancer Lett

January 2025

Department of Oral and Maxillofacial & Head and Neck Oncology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; National Center for Stomatology, National Clinical Research Center for Oral Diseases, Shanghai Key Laboratory of Stomatology, Shanghai, China. Electronic address:

Odontogenic neoplasms of the jaw are dominated by ameloblastoma (AM), a locally aggressive epithelial tumor with a significant propensity for recurrence. The World Health Organization's 2022 update to the AM classification system underscores recent progress in comprehending its underlying mechanisms and refining clinical approaches. Contemporary research has yielded significant insights into the genetic underpinnings of AM, paving the way for the development of precision-based treatment strategies.

View Article and Find Full Text PDF

Factors related to risk of recurrence and recurrence free survival in ameloblastoma of the Jaws: A single centre retrospective analysis.

Oral Maxillofac Surg

December 2024

Department of Oral and Maxillofacial Surgery, Faculty of Dental Sciences Institute of Medical Sciences, Banaras Hindu University, Varanasi Uttar Pradesh, 221001, India.

Purpose: Ameloblastoma is a benign tumor originating from odontogenic epithelium with a global incidence of about 0.5 cases per million persons per year. The overall recurrence rate of ameloblastomas range from 55% -90%.

View Article and Find Full Text PDF

Metabolic Analysis of Tumor Cells Within Ameloblastoma at the Single-Cell Level.

Oral Dis

December 2024

State Key Laboratory of Oral & Maxillofacial Reconstruction and Regeneration, Key Laboratory of Oral Biomedicine Ministry of Education, Hubei Key Laboratory of Stomatology, School & Hospital of Stomatology, Wuhan University, Wuhan, China.

Background: To meet their high energy needs, tumor cells undergo aberrant metabolic reprogramming. A tumor cell may expertly modify its metabolic pathways and the differential expression of the genes for metabolic enzymes. The physiological requirements of the host tissue and the tumor cell of origin mostly dictate metabolic adaptation.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!